7.8 years from diagnosis (0.33-12). On average, patients had 6.15 years of experience with their current medication; for 82% of them, the current TKI was first-line treatment. Results: Despite the fact that most patients (60%) reported having experienced some adverse effects, these were rarely perceived as serious or bothersome enough to lead to nonadherence. Patients scored consistently high on the necessity scale of the BMQ, but most showed at least 1 significant concern on the concern scale (87% with at least 1 score of ≥ 3). The MARS scores showed high adherence -79% scored 24 or 25 out of a 25-point maximum. This is in line with the fact that nearly all (95%) of the patients reported that they feel sufficiently educated about their disease and treatment. Results from questionnaires and demographic data were then correlated with TKI trough blood levels and response to the treatment with TKI to analyze prognostic impact of nonadherence. Final results will be presented at the conference. Conclusion: Thanks to well-conducted patient education, CML patients on TKI perceive the necessity of their treatment, as measured by the BMQ scale, and have good adherence rates, as measured by the BMQ and MARS scales and TKI trough blood levels, despite experiencing a significant number of side effects. Efficient patient education at our center that has resulted in better adherence level than reported in the previous studies is 1 of the most important preconditions for achievement of optimal response to TKI treatment. 
PP006-CLINICAL DISINTEGRATION TIME AND VOLUME OF WATER REQUIRED FOR ORALLY DISINTEGRATING TABLETS IN HEALTHY VOLUNTEERS
S. Uchida * ; T. Yoshita; S. Yagi; S. Hirata; T. Murao; S. Tanaka; and N. Namiki Pharmacy Practice & Science, University of Shizuoka, School of Pharmaceutical Sciences, Shizuoka, Japan Introduction: Orally disintegrating tablets (ODTs) disintegrate immediately in the mouth, and thus patients can consume them with little or without any water. These characteristics of ODTs are beneficial for patients who have difficulty swallowing conventional tablets (CTs) and also for patients with diseases in which water intake is restricted. In this study, we evaluated clinical disintegration time of 17 ODTs that are currently available for clinical use and determined the amount of water required to ingest ODTs and CTs. Patients (or Materials) and Methods: The clinical disintegration time was measured for 17 ODT products. Each tablet was placed on the tongues of healthy volunteers (n = 18), and disintegrated in their oral cavities. The clinical disintegration time of each ODT was measured by the investigator with a stopwatch. The residue in the oral cavity was removed and rinsed from the mouth with water after the test. In the measurement of the volume of water for ingesting of CTs and ODTs, which did not include any active pharmaceutical ingredients, all volunteers (n = 26) were asked to drink water while consuming CTs; while in the case of ODTs, they were asked to drink water after the ODT disintegrated in their oral cavity. They freely filled the cup with water from the 500-mL bottle and then drank the volume of water required to consume each tablet. The amount of water was measured using the weight of the cup and bottle. All study protocols were approved by the ethics committee of the University of Shizuoka. Results: To validate the method for measuring the clinical disintegration time of ODTs, the subjects were randomly assigned to 3 groups, and the clinical disintegration times of 2 ODTs were measured. No significant difference was observed in the clinical disintegration time of each ODT among the 3 groups, which indicated the reproducibility e19 of our method for measuring clinical disintegration time. The clinical disintegration time of the 17 ODT products was between 17.6 and 33.8 seconds in the clinical trial conducted with healthy adult volunteers. In the measurement of the amounts of water required for ingesting CTs and ODTs, no significant difference was observed in the amount of water required for ingesting CTs and ODTs among the 3 groups. The amount of water required for ingesting ODTs was significantly lesser than that required for ingesting CTs. Conclusion: This study demonstrates that all the tested products, which are clinically available in Japan, exhibit good disintegration and that the disintegration time varies by the product. This study also showed that the amount of water required for ingesting ODTs is lower than that required for ingesting CTs. Disclosure of Interest: None declared.
PP008-DRUG-RELATED PROBLEMS IN A GENERAL INTERNAL MEDICINE SERVICE
B. Guignard 1* ; C. Samer 2 ; A. Perrier 3 ; P. Bonnabry 1 ; P. Dayer 2 ; and J. Desmeules 2 1 Pharmacy; 2 Division of Clinical Pharmacology and Toxicology; and 3 Division of General Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland Introduction: Patients admitted to internal medicine wards receive a large number of drugs and are at risk of drug-related problems (DRPs) that may be associated with morbidity and mortality. In a French study, the in-hospital incidence rate of adverse drug reactions in internal medicine was 10.1 per 1000 patient-days and 80% of them could be considered preventable. The aim of the present study was to detect suboptimal drug use in 2 pilot wards of a general internal medicine service and to offer a pharmacologic and pharmaceutical evaluation to improve drug prescription. Patients (or Materials) and Methods: This was a prospective study conducted during 6 months in 2 internal medicine wards in a 2000bed university hospital. Physician rounds were attended once every other week in each ward by a clinical pharmacist and a clinical pharmacologist. All patients met during the physician rounds were included. Prescriptions were analyzed through an assessment grid to detect DRPs. Treatment optimizations were suggested to prescribers during the round. The main outcome measures were: (1) most frequent DRPs and involved drugs or drug classes; (2) types of intervention required: no intervention, verbal suggestion of treatment optimization, or specialized written consultation; and (3) acceptance rate by prescribers. Results: A total of 145 patients (mean age, 68 [21-99] ; 48% female) were included with 1523 prescriptions (mean, 10.6 [0-21] prescriptions per patient). A total of 383 DRPs were identified (mean, 2.6 [0-12] DRPs per patient). The most frequently identified DRPs were:
(1) drug interactions (21%); (2) untreated indications (18%); (3) overdosage (16%); and (4) drug used without a valid indication (10%). The most frequently involved drugs or drug classes were: (1) for drug interactions: tramadol, antidepressants, and acenocoumarol;
(2) for untreated indications: calcium-vitamin D, statins, and aspirin;
(3) for overdosage: proton pump inhibitors and paracetamol; and (4) for drug used without a valid indication: proton pump inhibitors and aspirin. Fifty-one percent of the identified DRPs were considered as clinically not relevant and were not reported to the prescribers, 42% were reported with a verbal suggestion of treatment optimization, and 7% were considered as complex and triggered a specialized written consultation by a clinical pharmacologist. Suggestions of treatment optimization were accepted by prescribers in 84% of cases. Accepted suggestions were applied by physicians in 64% of cases. Conclusion: The most frequently identified DRPs were drug interactions. One half of the identified DRPs required a suggestion of treat-ment optimization, which was accepted and applied by prescribers in most cases. Disclosure of Interest: None declared.
